- Home
- GH vs VKTX Comparison
GH vs VKTX Comparison
Compare GH & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- VKTX
- Stock Information
- Founded
- GH 2011
- VKTX 2012
- Country
- GH United States
- VKTX United States
- Employees
- GH N/A
- VKTX N/A
- Industry
- GH Medical Specialities
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- GH Health Care
- VKTX Health Care
- Exchange
- GH Nasdaq
- VKTX Nasdaq
- Market Cap
- GH 6.1B
- VKTX 4.7B
- IPO Year
- GH 2018
- VKTX 2015
- Fundamental
- Price
- GH $47.17
- VKTX $32.37
- Analyst Decision
- GH Strong Buy
- VKTX Strong Buy
- Analyst Count
- GH 15
- VKTX 12
- Target Price
- GH $42.57
- VKTX $106.75
- AVG Volume (30 Days)
- GH 2.6M
- VKTX 3.8M
- Earning Date
- GH 02-20-2025
- VKTX 02-05-2025
- Dividend Yield
- GH N/A
- VKTX N/A
- EPS Growth
- GH N/A
- VKTX N/A
- EPS
- GH N/A
- VKTX N/A
- Revenue
- GH $692,256,000.00
- VKTX N/A
- Revenue This Year
- GH $32.40
- VKTX N/A
- Revenue Next Year
- GH $16.92
- VKTX N/A
- P/E Ratio
- GH N/A
- VKTX N/A
- Revenue Growth
- GH 29.20
- VKTX N/A
- 52 Week Low
- GH $15.81
- VKTX $23.11
- 52 Week High
- GH $50.89
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- GH 66.04
- VKTX 33.65
- Support Level
- GH $44.10
- VKTX $32.77
- Resistance Level
- GH $50.89
- VKTX $34.78
- Average True Range (ATR)
- GH 2.75
- VKTX 2.05
- MACD
- GH 0.21
- VKTX 0.27
- Stochastic Oscillator
- GH 74.24
- VKTX 33.46
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.